Kératene Retard - new non-steroidal DHT depressor

 In the past two decades, there is little to no concrete progress recorded in terms of research, development and efficient clinical testing of new substances that have DHT-lowering properties. Since 2010 however, there is new research on the field of endocrinologic effects of various substances on DHT and its precursor, as well as the impact of these compounds on our daily bodily functions. We present some technical information about Kératene alphactive Retard, a new product recently announced in various international scientific forums, for its DHT-lowering properties. There are recent in vivo tests performed on this product and here are some interesting conclusions that this product could be useful in relation to hair loss.

A new chance to stop baldness

Analyzing the results of the latest in vivo tests conducted on adult males medicated with the synthetic counterpart from the -steride group, we observed that this substance has a tremendous chemical potential to send DHT into a deep depression, under the biologically acceptable limits for adult males. In a side-by-side comparison, test subjects got very low DHT values, varying between 190 and 250 pg/ml. After 12 to 16 months of continuous administration, the test subjects reported onset of gynaecomastia combined with low athletic tonus, depressed libido tonic state, all the direct effect of severely depressed DHT levels, for sustained periods of time. 

Based on the current clinical endocrinologic recommendations, maintaining male DHT levels between 400 and 800 pg/ml is an intrinsic condition for a healthy active male as well as for the exclusion of the onset of gynaecomastia.

Once the test subjects stopped the –steride-based medication, the DHT level bounced back to its “natural” level, after 4 to 5 days. Notably, DHT recovered from 200 pg/ml to 1995 pg/ml in a timeframe of 7 consecutive days, rising rapidly, in geometric progression. This translates into the conclusion that –steride-based substances have a low bio-accumulation time in healthy males, with a native substance half-life of up to 72 hours.

In contrast to the above substance, Kératene alphactive Retard reduced the DHT level to 390 – 430 pg/ml in just 6 to 7 days from administration, stabilizing its level at an average of 490 pg/ml, after 10 to 12 days of therapy, depending on the subject’s internal endocrine dynamics. The reduction curve produced by Kératene alphactive Retard follows a harmonic trend, mathematically elegant, without major shocks, whereas its counter-part acts in acute drops (super dip). The long-term stabilization mechanism employed by Kératene alphactive Retard depends on the personal endocrinologic profile and other internal factors and the exact values may vary discretely from individual to individual.

Also notable, unlike its synthetic counterpart from the –steride group, Kératene alphactive Retard does not penetrate the BB Barrier and it has no impact on Lutropin, DHEA or on sbhg. The analytical tests also showed that the compound does not suppress endocrine precursors, does not inhibit the enzyme production, does not inhibit the acceptor androgen T and it has no effect on the libido. Moreover, we observed FT and TT levels were stable through-out the trial, indicating not only that TT remains within safe limits but also the unmodified bio-availability of FT for immediate muscular metabolism. 

Based on the clinical results obtained from our study group, it is reasonable to state that Kératene alphactive Retard may have an equipotent main effect as the current existing medical solutions, while not exhibiting the typical drug-induced side-effects. 

This particular aspect might be of interest for the patients on synthetic DHT depressors from the –steride group. We also recommend to consult periodically the latest health warnings related to synthetic depressors from the –steride group, posted on the FDA site. 

There are new significant developments that might be of special interest to the medical staff as well as patients (see the recent findings of increased risks on malignant prostate neoplasm in men medicated with substances from the –steride group).

By providing the preliminary data as constructed above, we do not endorse in any way the use of the herein described substances without professional medical supervision. More details will be made at a later date.